Palopegteriparatide

Palopegteriparatide (Transcon PTH) is a prodrug of parathyroid hormone PTH 1-34, which can maintain normal and stable calcium concentrations without the need for calcium and active vitamin D replacement. Palopegteriparatide can be used in research on hypoparathyroidism[1][2].

2222514-07-8

Transcon PTH; ACP-014

12352209

Others

Others

Metabolism-protein/nucleotide metabolism

Endocrinology

10 mM in DMSO

[{X}-Ser-Val-Ser-Glu-Ile-Gln-Leu-Met-His-Asn-Leu-Gly-Lys-His-Leu-Asn-Ser-Met-Glu-Arg-Val-Glu-Trp-Leu-Arg-Lys-Lys-Leu-Gln-Asp-Val-His-Asn-Phe(X=O-methylpolyethyleneglycol(2x20kDamPEG)-Aib)]

[1]Khan AA, et al. Efficacy and Safety of Parathyroid Hormone Replacement With TransCon PTH in Hypoparathyroidism: 26-Week Results From the Phase 3 PaTHway Trial. J Bone Miner Res. 2023;38 (1) :14-25.|[2]Kontogeorgos G. Parathyroid Hormone Hyper-and Hypoparathyroidism Effect of Treatment and Long-term Follow-up Studies[M]. 2024.

Room temperature

http://file.medchemexpress.com/batch_PDF/HY-P10277/

Peptides

Launched